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Poor in vivo persistence and loss of function of adoptively
transferred T cells in the tumor milieu are known short-
comings of adoptive T cell therapy (ATT). Providing costi-
mulation might help to improve ATT efficiency. However,
human CD8 T effector cells are largely CD28 negative and
most tumors do not express CD80 or CD86, thus costimu-
lation cannot be provided via CD28 ligation. We propose
to facilitate costimulation of CD8 T effector cells in the
tumor milieu through engineering of T cells with a chi-
meric signaling receptor, which can turn tumor mediated
inhibition into activation by abrogating inhibitory PD1 sig-
naling with concomitant activation of the costimulatory
pathway. Human T cells engineered to express melanoma
specific T cell receptors (TCR) plus the chimeric signaling
molecule showed higher ERK phosphorylation associated
with stronger IL-2 and IFN-g secretion upon co-culture
with PD-L1 positive target cells. T cells expressing a low
avidity TCR achieved functional responses comparable to
high avidity TCRs when engineered with the chimeric
receptor. The chimeric receptor did not only increase
cytokine secretion in vitro, but importantly, also supported
intra-tumoral proliferation of T cells in a humanized
mouse melanoma model.
Authors’ details
1Institute of Molecular Immunology, Helmholtz Center Munich, German
Research Center for Environmental Health, Munich, Germany. 2Max Delbrück
Center for Molecular Medicine, Helmholtz Association, Berlin, Germany.
3Institute of Biology, Humboldt-University, Berlin, Germany.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P248
Cite this article as: Schlenker et al.: Turning tumor inhibition into
activation: engineering T cells with chimeric signaling receptors. Journal for
ImmunoTherapy of Cancer 2014 2(Suppl 3):P248.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
1Institute of Molecular Immunology, Helmholtz Center Munich, German
Research Center for Environmental Health, Munich, Germany
Full list of author information is available at the end of the article
Schlenker et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P248
http://www.immunotherapyofcancer.org/content/2/S3/P248
© 2014 Schlenker et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
